Milestone Pharmaceuticals NASDAQ: MIST said its first quarter of 2026 marked the beginning of commercial sales for CARDEMYST, its newly approved treatment for acute episodes of paroxysmal supraventricular tachycardia, or PSVT, while the company also moved ahead with a Phase 3 program in atrial fibrillation with rapid ventricular rate. Get MIST alerts: Oliveto said Milestone made the product available through retail pharmacies by the end of January and began promotion in earnest in mid-February, including de ...

Milestone Pharmaceuticals (NasdaqGS:MIST) Q1 2026 Earnings call May 13, 2026 08:30 AM ET Company Participants Amit Hasija - CFO and EVP of Corporate Development Brandon Folkes - Managing Director Joseph Oliveto - President and CEO Lorenz Muller - CCO Michael Wood - Managing Director Mohit Bansal - Managing Director Ritu Baral - Managing Director Ted Tenthoff - Managing Director Tiago Fauth - Managing Director Conference Call Participants None - Analyst Operator Ladies and gentlemen, good morning, and welcom ...

Milestone Pharmaceuticals (NasdaqGS:MIST) Q1 2026 Earnings call May 13, 2026 08:30 AM ET Company Participants Amit Hasija - CFO and EVP of Corporate Development Brandon Folkes - Managing Director Joseph Oliveto - President and CEO Lorenz Muller - CCO Michael Wood - Managing Director Mohit Bansal - Managing Director Ritu Baral - Managing Director Ted Tenthoff - Managing Director Tiago Fauth - Managing Director Conference Call Participants None - Analyst Operator Ladies and gentlemen, good morning, and welcom ...

Milestone Pharmaceuticals (NasdaqGS:MIST) Q1 2026 Earnings call May 13, 2026 08:30 AM ET Speaker7Ladies and gentlemen, good morning, and welcome to the Milestone Pharma First Quarter 2026 Earnings Conference Call. At this time, all participants are in listen-only mode. A brief question-and-answer session will follow the formal presentation. If anyone requires operator assistance during the conference, please signal the operator by pressing star and zero on your telephone keypad. As a reminder, this conferen ...